

Pant S et al. *JAMA Oncol.* 2026;12(1):106–109.

[Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01 | Trials | JAMA Oncology | JAMA Network](#)